pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,773 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT780Endpoints580BioPharma Dive224onclive165BioSpace56Fierce Biotech54raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • WuXi AppTec seeks injunction over China military list
    WuXi AppTec has filed for a preliminary injunction to suspend its place on the Pentagon’s list of companies with alleged ties to the Chinese military. The injunction, dated June 29, seeks to stop…
    Endpoints · 25d ago↗ source
  • FDA approves Orca Bio’s cell therapy to improve transplant outcomes
    The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients. The therapy will be branded as Tregzi, an homage to the regula…
    Endpoints · 25d ago↗ source
  • BridgeBio gets funding for drug launch; United buys into cell therapy
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
← prev
page 20 of 71
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 25d ago
↗ source
  • STAT+: The moment Anthropic convinced me it’s serious about science
    AI Prognosis: The release of Claude Science suggests big model makers are getting serious about real science, and not just flashy problems.
    STAT · 25d ago↗ source
  • BridgeBio adds $1B as it prepares three more drug launches
    BridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for…
    Endpoints · 25d ago↗ source
  • STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?
    Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists.  It’s a piece…
    STAT · 25d ago↗ source
  • Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
    <figure><div><img src="https://imgproxy.divecdn.com/rFr9RThJC2782402VMoj7B8WOeODiV2bfIpEN0A2SvU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS84LmpwZw==.webp"/></div></figure><p…
    BioPharma Dive · 25d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more
    Anthropic announced the availability of Claude Science, which optimizes its large language model for use in scientific labs and by drugmakers
    STAT · 25d ago↗ source
  • STAT+: More signs that GLP-1s may help with peripheral artery disease
    Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout
    STAT · 25d ago↗ source
  • 92Bio revives a T cell engager it had transferred to Amgen
    A small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…
    Endpoints · 25d ago↗ source
  • Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data
    🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…
    Endpoints · 25d ago↗ source
  • 5 FDA decisions to watch in the third quarter of 2026
    <figure><div><img src="https://imgproxy.divecdn.com/ZralPibwV2FS7gfl92V7anvyG-GCm_2yJ_lZgP4LM4k/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8yRENKUkI1LmpwZw==.webp"/></div></f…
    BioPharma Dive · 25d ago↗ source
  • Abivax shares surge as worries subside over immune drug’s cancer risk
    <figure><div><img src="https://imgproxy.divecdn.com/4eoVQHFTAvljHZA3dtwvKrrS1WlgcrV7_wLUFGcZYWw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjMwMTMxMDIyXzEua…
    BioPharma Dive · 25d ago↗ source
  • FDA says Zyn can market its pouches as safer than cigarettes
    The influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning Rounds
    STAT · 25d ago↗ source
  • STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients
    The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.
    STAT · 25d ago↗ source
  • Ipsen to scoop up Memo Therapeutics and its kidney infection drug
    Ipsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...
    Endpoints · 25d ago↗ source
  • A June flourish lifts biotech megaround tally in first half of 2026
    Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally. That's more than the same period of 2025 ...
    Endpoints · 25d ago↗ source
  • STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes
    Demand for alcohol is declining. The industry is fighting harder and more creatively than ever against limits — and winning.
    STAT · 26d ago↗ source
  • STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
    Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
    STAT · 26d ago↗ source
  • Opinion: Maryland Gov. Wes Moore: How to improve young men’s mental health
    “We need to stop treating our young men and boys as problems to be solved, and start treating them as people to be invested in,” writes Gov. Wes Moore.
    STAT · 26d ago↗ source
  • Opinion: What Ebola and Marburg are teaching us about the next pandemic
    “What is urgently needed is a shift from pathogen-specific diagnostics toward pathogen-agnostic diagnostic systems,” write Krutika Kuppalli and Placide Mbala.
    STAT · 26d ago↗ source
  • STAT+: AI company Anthropic announces it will begin developing drugs of its own
    AI giant Anthropic has already become a dominant player in technology and a household name for everyday users of artificial intelligence. Can it make drugs too?
    STAT · 26d ago↗ source
  • Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 26d ago↗ source
  • Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congress
    Depression, the New Jersey congressman said, “is physical, it is emotional, and until you experience it yourself, it is difficult to fully understand how powerful this illness can be.”
    STAT · 26d ago↗ source
  • FDA reviewers oppose allowing seven peptides for compounding
    Ahead of an FDA advisory committee meeting to discuss lifting restrictions on seven popular peptides, agency reviewers have recommended against including the peptides on a list of bulk drug substan…
    Endpoints · 26d ago↗ source